Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice

Gagliato, Débora De Melo; Cortés, Javier; Curigliano, Giuseppe; Loi, Sherene; Denkert, Carsten; Peréz-García, José Manuel; Holgado, Esther

doi:10.1016/j.bbcan.2017.10.003

Cited by 64 publications

(54 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor‐infiltrating CD8 + CTLs exhibited antitumor immunity and showed a favorable outcome in patients with breast cancer . Even though breast cancers are not widely considered as “immunogenic,” nevertheless, it has been demonstrated, in some subgroups of patients, that TILs in the stroma are correlated with favorable outcomes . Many studies showed that the immune environment impacts the outcome of breast cancer, especially aggressive subgroups such as nonluminal ones.…”

Section: Role Of T Cell Subsets In Tumor Immunitymentioning

confidence: 99%

T lymphocyte subsets in cancer immunity: Friends or foes

Chraa

Naim

Olive

et al. 2018

Journal of Leukocyte Biology

127

View full text Add to dashboard Cite

Although immune-based therapy is proving to be a success in several cancer types, only a set of patients appear to respond to immune checkpoint blockade including PD-1 and CTLA-4. A better understanding of the crucial components of cancer immunity is therefore necessary. T lymphocytes, a key element, are found within the tumor microenvironment and seem to be critical in determining the efficacy of immune surveillance. In this review, we will depict the pro-and antitumor roles of major T cell subsets in distinct cancer tissues. The central role of the mainly antitumor subsets, cytotoxic T cells and Th1 cells, will be delineated. Subsequently, we will indicate how other subsets including Th2, Th17, and T regulatory cells exhibit ambivalent roles. We will also describe the emerging and favorable role of Th9 cells in cancer immunity. In parallel, we will go through main mechanisms by which these cells operate, and will pinpoint pathways, which could be used as potential therapeutic targets in order to positively impact the immune response and ameliorate patients' clinical outcome.

show abstract

Section: Role Of T Cell Subsets In Tumor Immunitymentioning

confidence: 99%

T lymphocyte subsets in cancer immunity: Friends or foes

Chraa

Naim

Olive

et al. 2018

Journal of Leukocyte Biology

127

View full text Add to dashboard Cite

show abstract

“…Cumulating evidence indicates that tumor infiltrating lymphocytes (TILs) play an active role in controlling progression and clinical outcome in breast cancer, particularly in highly proliferative TNBC and HER2 + cancers [210][211][212] , and in conjunction with chemotherapy [213,214] . This is particularly relevant to TNBC, as these cancers present the richest presence of TILs, most notably CD8 + T lymphocytes, and tertiary lymphoid structures [211,215,216] .…”

Section: Immune Response and Chemotherapy In Breast Cancermentioning

confidence: 99%

“…A second approach to consider, is to exploit the ability of chemotherapy to elicit an effective immune response in breast cancer, particularly in lymphocyte-infiltrated TNBC or HER2 + tumors [211,212,222,224,226,227,259] . Strategies to improve chemotherapy-induced immunological dormancy.…”

Section: Neoadjuvant Chemotherapymentioning

confidence: 99%

Chemotherapy-induced immunological breast cancer dormancy: a new function for old drugs?

Peyvandi¹,

Lan²,

Lorusso³

et al. 2019

JCMT

View full text Add to dashboard Cite

Breast cancer remains the main cause of cancer-related mortality for women worldwide. Main cause of death is the development of therapy-resistant metastases. Relapses occur with a bimodal temporal distribution, with a first peak at 1-2 years after initial therapy and a second peak 2-3 years later. This discontinuous growth kinetics is consistent with the notion that disseminated cancer cells can remain dormant over a prolonged period of time before resuming growth. How cancer cells enter, sustain and exit dormancy, are unanswered questions with relevance to cancer biology, monitoring and therapy. Investigating mechanisms of breast cancer dormancy remains challenging, as in patients the condition is elusive and experimentally there are only a few models that recapitulate the clinical condition. Thus, developing new models to identify clinically relevant mechanisms and candidate therapeutic targets may open new avenues for novel therapies to induce and prolong dormancy. We have observed that cells surviving chemotherapy can enter a state of immunological dormancy. Using this model, we identified IRF-7/Interferon type I/IFNRA as signaling axis essential for this effect. Here we will review concepts and recent developments in cancer metastasis and dormancy with emphasis on breast cancer, and elaborate strategies to exploit them therapeutically.

show abstract

“…Substantive tissue and tumor subtype-specific differences of multiple cell types, in particular TILs, have been identified in BC subtypes, and in particular TNBC and HER2/neu-negative BC exhibit a unique TME distinct from that of other BC subtypes. Immunohistochemical analyses have demonstrated that CD8+ CTL, known to contribute to tumor clearance, were associated with good prognosis and long-term survival [80] and are thus of clinical relevance [81]. Furthermore, the number of tumor-infiltrating CD8+ T cells was associated with primary tumor size, lymph node metastasis, WHO (World Health Organization) grade, Ki-67, and molecular classification.…”

Section: Tumor Microenvironment In Breast Cancermentioning

confidence: 99%

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer

2018

View full text Add to dashboard Cite

While detailed analysis of aberrant cancer cell signaling pathways and changes in cancer cell DNA has dominated the field of breast cancer biology for years, there now exists increasing evidence that the tumor microenvironment (TME) including tumor-infiltrating immune cells support the growth and development of breast cancer and further facilitate invasion and metastasis formation as well as sensitivity to drug therapy. Furthermore, breast cancer cells have developed different strategies to escape surveillance from the adaptive and innate immune system. These include loss of expression of immunostimulatory molecules, gain of expression of immunoinhibitory molecules such as PD-L1 and HLA-G, and altered expression of components involved in apoptosis. Furthermore, the composition of the TME plays a key role in breast cancer development and treatment response. In this review we will focus on i) the different immune evasion mechanisms used by breast cancer cells, ii) the role of immune cell infiltration in this disease, and (iii) implication for breast cancer-based immunotherapies.

show abstract

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice

Cited by 64 publications

References 95 publications

T lymphocyte subsets in cancer immunity: Friends or foes

T lymphocyte subsets in cancer immunity: Friends or foes

Chemotherapy-induced immunological breast cancer dormancy: a new function for old drugs?

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer

Contact Info

Product

Resources

About